CING

Cingulate Inc.

5.18 USD

Last updated Sep 5, 11:10 UTC

Yesterday HIGH

$5.5

Yesterday LOW

$5.02

52w HIGH

$11.89

52w LOW

$3.16

EPS

-0.45

PE

-11.51

Next Earnings

Nov 12, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Cingulate Inc. stock is up 2.57% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 4 September’s closed higher than August. In the last 8 Unusual Options Trades, there were 1 PUT, 7 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

13 Jul 14:48	20 Nov, 2026	2.50	PUT	1010	1030
14 Jul 19:23	19 Feb, 2027	5.00	CALL	200	812
17 Jul 17:39	19 Feb, 2027	5.00	CALL	130	1134
17 Jul 17:53	19 Feb, 2027	5.00	CALL	330	1134
20 Jul 17:11	19 Feb, 2027	5.00	CALL	322	1595
20 Jul 19:11	19 Feb, 2027	5.00	CALL	300	1595
21 Jul 19:51	19 Feb, 2027	5.00	CALL	537	2702
21 Aug 16:22	19 Feb, 2027	5.00	CALL	200	4021

Advanced Data Unlock

Benzinga Newsdesk

Tue Jun 2, 2026

Cingulate shares are trading higher after the company announced that the FDA has issued a Complete Response Letter for its NDA for CTx-1301 for the treatment of Attention Deficit/Hyperactivity Disorder.
Benzinga Newsdesk

Tue Jun 2, 2026

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Tue Jun 2, 2026

Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy

The response identified specific Chemistry, Manufacturing and Controls (CMC) information requests and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301. Cingulate expects a prompt
Benzinga Newsdesk

Tue Jun 2, 2026

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk

Tue May 26, 2026

Cingulate shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $20 price target.
Benzinga Newsdesk

Tue May 26, 2026

HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:CING) with a Buy and maintains $20 price target.
Benzinga Newsdesk

Thu May 14, 2026

Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate

Cingulate (NASDAQ:CING) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.53) by 79.25 percent. This is a 10.38 percent increase over losses of $(1.06) per share from the
Benzinga Insights

Wed Apr 22, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session
Avi Kapoor

Wed Apr 8, 2026

Amazon To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday

Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings page. Price targets and ratings altered for CING, WING, DEFT, FANG, PJT, DOCS, and AMZN.
Benzinga Newsdesk

Wed Apr 8, 2026

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $55

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $58 to $55.

Roth Capital

Mon Aug 24, 19:04

buy

confirm
Ascendiant Capital

Thu Aug 20, 11:53

buy

confirm

Advanced Data Unlock

NFLX $78.29 USD

LKNCY $0.00 USD

ETH ETH $23.42 USD

ONON $27.99 USD

MUZ MUZ $8.26 USD

DIA $532.33 USD

NCLH $15.56 USD